Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

医学 铜绿假单胞菌 囊性纤维化 妥布霉素 养生 内科学 抗生素 临床终点 外科 临床试验 胃肠病学 微生物学 遗传学 生物 细菌
作者
Felix A. Ratjen,À. Munck,Pearl Kho,Gerhild Angyalosi,for the ELITE Study Group
出处
期刊:Thorax [BMJ]
卷期号:65 (4): 286-291 被引量:319
标识
DOI:10.1136/thx.2009.121657
摘要

RATIONALE: Antibiotic therapy for early Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) is effective, but the optimal therapeutic regimen and duration for early treatment remains unclear. The EarLy Inhaled Tobramycin for Eradication (ELITE) study was designed to assess the efficacy and safety of two regimens (28 and 56 days) of tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for the treatment of early onset P aeruginosa infection in patients with CF. METHODS: In this open-label randomised multicentre study, patients with CF (aged > or = 6 months) with early P aeruginosa infection were treated for 28 days with TIS twice daily administered by the PARI LC PLUS (PARI GmbH, Starnberg, Germany) jet nebuliser. After 28 days, patients were randomised 1:1 to either stop TIS (n=45) or to receive a further 28 days of TIS (n=43). The primary endpoint was the median time to recurrence of P aeruginosa (any strain). Secondary endpoints included the proportion of patients free of P aeruginosa infection 1 month after cessation of therapy and safety assessments. RESULTS: The median time to recurrence of P aeruginosa (any strain) was similar between the two groups. In total, 93% and 92% of the patients were free of P aeruginosa infection 1 month after the end of treatment and 66% and 69% remained free at the final visit in the 28-day and 56-day groups, respectively. TIS was well tolerated. CONCLUSIONS: Treatment with TIS for 28 days is an effective and well tolerated therapy for early P aeruginosa infection in patients with CF. TRIAL REGISTRATION NUMBER: NCT00391976.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
uilyang完成签到,获得积分20
刚刚
1秒前
情怀的应助被千跃采纳,获得10
1秒前
1秒前
zijin完成签到,获得积分10
2秒前
粗心的若发布了新的文献求助10
2秒前
动听衬衫发布了新的文献求助10
3秒前
iuk完成签到,获得积分10
4秒前
相看两厌完成签到,获得积分10
5秒前
5秒前
李盈盈完成签到,获得积分20
6秒前
cindy完成签到,获得积分10
6秒前
As故完成签到,获得积分10
6秒前
6秒前
7秒前
笑点低愫完成签到,获得积分10
7秒前
iuk发布了新的文献求助10
8秒前
As故发布了新的文献求助10
8秒前
NEtizy完成签到 ,获得积分10
9秒前
NexusExplorer的应助被千跃采纳,获得10
9秒前
李燕伟发布了新的文献求助10
9秒前
laaaaaplace完成签到,获得积分10
11秒前
靳南希完成签到,获得积分10
11秒前
11秒前
orixero的应助被luxiaoyu采纳,获得10
12秒前
12秒前
kingham关注了科研通微信公众号
12秒前
Ren的应助被daomaihu采纳,获得100
12秒前
lhxie完成签到,获得积分10
12秒前
Ren的应助被daomaihu采纳,获得100
12秒前
Ren的应助被daomaihu采纳,获得100
12秒前
科研通AI6.2的应助被粗心的若采纳,获得10
12秒前
12秒前
Ren的应助被daomaihu采纳,获得100
12秒前
顺心觅风发布了新的文献求助10
12秒前
Ren的应助被daomaihu采纳,获得100
12秒前
丁庆亮完成签到,获得积分10
13秒前
6366336发布了新的文献求助10
13秒前
13秒前
小马甲的应助被fsxadada123采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496